Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents

Safety and Risk of Pharmacotherapy
doi 10.30895/2312-7821-2020-8-1-9-22
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SCEEMP